Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 80, n° 6
pages 1533-1537 (juin 2019)
Doi : 10.1016/j.jaad.2019.02.004
accepted : 2 February 2019
Original Articles

Overall and subgroup prevalence of pyoderma gangrenosum among patients with hidradenitis suppurativa: A population-based analysis in the United States
 

Rachel Tannenbaum, BA, Andrew Strunk, MA, Amit Garg, MD
 Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra Northwell, New Hyde Park, New York 

Correspondence to: Amit Garg, MD, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 1991 Marcus Ave, Suite 300, New Hyde Park, NY 11042.Donald and Barbara Zucker School of Medicine at Hofstra/Northwell1991 Marcus AveSuite 300New Hyde ParkNY11042
Abstract
Background

Hidradenitis suppurativa (HS) and pyoderma gangrenosum (PG) are reported to coexist, although the prevalence of PG among patients with HS has not been systematically evaluated.

Objective

To evaluate PG prevalence among patients with HS.

Methods

Cross-sectional analysis of adults with PG among patients with HS and patients without HS through use of electronic health records data from a population-based sample of 55 million patients.

Results

The prevalence of PG among 68,232 patients with HS was 0.18% (125 of 68,232), compared with 0.01% (1835 of 31,435,166) among those without HS (P  < .0001). Prevalence was markedly higher among patients with HS and Crohn's disease (CD) (3.68%) than among patients with HS but without CD (0.12%). The odds of having PG were 21.14 (95% confidence interval [CI], 17.51-25.51) times greater among patients with HS than among those without HS. Patients with HS with CD had 12.38 (95% CI, 9.15-16.74) times the odds of having PG than did patients without HS but with CD. Among patients without CD, compared with patients without HS, those with HS had 26.51 (95% CI, 21.07-33.36) times the odds of having PG.

Limitations

We could not establish HS phenotype among those having coexistent PG, nor could we distinguish syndromic from nonsyndromic cases.

Conclusion

Patients with HS have an increased prevalence of PG, regardless of CD status. Painful ulcerations among patients with HS warrant additional evaluation for PG.

The full text of this article is available in PDF format.

Key words : acne, ankylosing spondylitis, conglobata, Crohn's disease, Explorys, hidradenitis suppurativa, PADH, PAPASH, PASS, pyoderma gangrenosum, pyogenic arthritis

Abbreviations used : CI, HS, ICD, ICD-9, PAPASH, PASH, PASS, PG, SNOMED-CT



 Funding sources: Supported in part by an education grant from AbbVie. The sponsor had no role in the design and conduct of the study; collection, management, analysis and interpretation of data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
 Disclosure: Dr Garg has served as an advisor for AbbVie, Pfizer, Janssen, Asana Biosciences, and UCB and has received honoraria. Ms Tannenbaum and Mr Strunk have no conflicts of interest to disclose.
 Reprints not available from the authors.



© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline